Cargando…
EPM2A acts as a protective factor in prostate cancer, evidence from a real-world patient cohort
EPM2A encodes a dual specificity phosphatase and has been proven to be a potential biomarker in several cancers but has not been mentioned in prostate cancer (PCA). We investigated the prognostic and therapeutic value of EPM2A in PCA. The TCGA-PRAD cohort was collected to evaluate the differential e...
Autores principales: | Ge, Qintao, Li, Jiawei, Tao, Junyue, Gao, Rui, Jin, Chen, Zhou, Jun, Zhang, Meng, Hao, Zongyao, Meng, Jialin, Liang, Chaozhao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527317/ https://www.ncbi.nlm.nih.gov/pubmed/36199693 http://dx.doi.org/10.3389/fphar.2022.946637 |
Ejemplares similares
-
Overexpression of DDX49 in prostate cancer is associated with poor prognosis
por: Tao, Junyue, et al.
Publicado: (2023) -
Molecular classifications of prostate cancer: basis for individualized risk stratification and precision therapy
por: Ge, Qintao, et al.
Publicado: (2023) -
Protective trend of anti-androgen therapy during the COVID-19 pandemic: A meta-analysis
por: Meng, Jialin, et al.
Publicado: (2022) -
Integrated multi‐omics data reveals the molecular subtypes and guides the androgen receptor signalling inhibitor treatment of prostate cancer
por: Meng, Jialin, et al.
Publicado: (2021) -
Tumor immune microenvironment-based classifications of bladder cancer for enhancing the response rate of immunotherapy
por: Meng, Jialin, et al.
Publicado: (2021)